Article Text

Download PDFPDF

#992 The use of CA-125 KELIM to identify which patients can achieve complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer
  1. Dimitrios Zouzoulas1,
  2. Panagiotis Tzitzis1,
  3. Dimitrios Tsolakidis1,
  4. Vasilis Theodoulidis1,
  5. Kimon Chatzistamatiou1,
  6. Maria Topalidou2 and
  7. Grigoris Grimbizis1
  1. 11st Department of Obstetrics and Gynecology, AUTh, Thessaloniki, Greece
  2. 2Radiotherapy Department, Thessaloniki, Greece


Introduction/Background Neoadjuvant chemotherapy followed by interval debulking surgery is used in the treatment of advanced ovarian cancer. However, no tool can safely predict if complete cytoreduction after 3–4 cycles can be achieved. KELIM is a modeled kinetic parameter based on CA-125 values measured during the first 100 days of neoadjuvant chemotherapy. This study aims to investigate if KELIM score can be a tool in the identification of patients that can achieve a complete interval debulking surgery (IDS).

Methodology We retrospectively analyzed the records of patients with advanced ovarian cancer that were treated in the 1st Department of Obstetrics – Gynecology Clinic from 2012 – 2022 with neoadjuvant chemotherapy followed by IDS. Patient characteristics, oncological and follow-up information were collected. KELIM score was measured with the online tool, The primary outcome was the association of KELIM score and residual disease.

Results Out of 128 patients, 83 had the available data to be included in the final analysis. Patients were categorized into two groups: Group A (51 patients) favorable (≥1) and Group B (32 patients) unfavorable (<1) KELIM scores. There was no statistically significant difference in age, BMI, comorbidities, postoperative complications, and hospital stay between the two groups. However, statistically significant correlation between KELIM and residual disease (p<0.05) exists, showing that patients with a favorable KELIM score can achieve a complete IDS. There was only one case with favorable KELIM that led to an optimal cytoreduction, because of milliary disease in the small bowel. Concerning survival rates, there was a statistically significant difference in overall survival (p=0.0176), but no difference was observed in progression-free survival (p=0.143).

Conclusion KELIM seems to be a tool to safely triage patients after neoadjuvant chemotherapy and decide who can undergo IDS, while patients with unfavorable KELIM score can undergo diagnostic laparoscopy, to assess tumor resectability.

Disclosures No disclosures

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.